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Summary 
This multicenter randomized, double-blind, controlled study was performed to compare the efficacy and 
tolerability of chondroitin sulfate (CS, Condrosulf R::, IBSA, Lugano, CH) 1200 mg/day oral gel vs CS 
3 x 400 mg/day capsules vs placebo, in patients with mono or bilateral knee osteoarthritis (Kellgren and 
Lawrence radiographic score grade I to Ill). A total of 127 patients, 40 of whom were treated with CS 
1200 mg/day, 43 with CS 3 x400 mg/day and 44 with placebo, were included in the statistical analysis of 
this 3-month treatment s udy. In the CS groups, Lequesne's Index and spontaneous joint pain (VAS) showed 
a significant reduction of clinical symptoms (P < 0.01 for both parameters), while only a slight reduction 
was observed in the placebo group (P= ns for Lequesne's Index and P < 0.05 for VAS). 
The physician's and patient's overall efficacy assessments were significantly in favour of the CS groups 
(P < 0.01). The treatment carried out with the three formulations was very well tolerated. 
In conclusion, these results indicate that CS favours the improvement of the subjective symptoms, 
improving the joint mobility. An additional consideration is that the efficacy of 1200 mg CS as a single daily 
dose does not differ from that of 3x400 mg daily doses of CS for all the clinical parameters taken into 
consideration. 
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Motive of the study 
CHONDROITIN sulfate (Condrosulf", IBSA, 
Lugano, Switzerland) administered at a dosage of 
1200 mg divided into three doses per day has now 
become a part of the therapeutic armoury of the 
French rheumatologist. If the quantity of active- 
drug could be absorbed following administration 
of a single daily dose, this would enhance the 
patient's compliance. 
Aim of the study 
The aim of this trial was to assess the efficacy 
and toterability of a new presentation of chon- 
droitin sulfate CS 4&6, in sachets of oral gel at 
1200 mg (CS 1200) as a single daily dose, vs three 
daily doses of chondroitin sulfate CS 4&6 in 
Supplement sponsored by IBSA (Switzerland)/Laboratoires 
GENEVRIER (France). 
capsules of 400 mg (CS 3x400) and vs a placebo 
(PBO). 
Methods 
This was a 3-month phase III, randomized, 
double-blind, double-dummy, in parallel groups 
clinical trial. The sample size was estimated to be 
40 patients/group (CS 1200 group, CS 3 x 400 group 
and placebo group). 
PATIENTS 
Outpatients of either sex, aged > 45 years, with 
femoraI-tibiaI knee osteoarthritis, internal or 
external (according to Altman criteria, ACR), 
unilateral or bilateral, of stages I to III, which 
implies conservation of an articular joint space, 
and requiring the stable daily administration of
one of the authorized NSAIDs for at least 1 month 
before the trial, were eligible for the trial. 
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Patients with peptic gastroduodenal ulcers, 
renal dysfunction, or severe organic diseases as 
well as pregnant and lactating women were 
excluded from the study. 
Medications for co-existing diseases or con- 
ditions could be administered uring the study 
with the exception of SYSADOA, steroids (oral 
or parenteral), bone-oriented therapies (fluoride, 
biphosphonates, calcitonin, hormonal substi- 
tution). 
All patients gave their written informed consent 
to participate in the study, which was carried out 
in accordance with the Helsinki Declaration and 
its subsequent amendments. 
TEST DRUGS, DOSAGE AND ADMINISTRATION 
To preserve the double blind condition of the 
study, chondroitin sulfate CS 4&6 oral gel at 
1200mg (CS 1200) and placebo oral gel were 
available in sachets of identical appearance, as 
well as chondroitin sulfate CS 4&6 capsules of 
400 mg (CS 3 • 400) and placebo capsules. 
During the 3 months of the study, patients 
assigned to the CS 1200 group took one sachet of 
oral gel CS at 1200 mg and one placebo capsule in 
the morning, then one placebo capsule at noon and 
one placebo in the evening. 
Patients assigned to the CS 3• group took 
one sachet of placebo oral gel and one capsule of 
400 mg CS in the morning, one capsule of 400 mg 
CS at noon and one capsule of 400 mg CS in the 
evening. 
Patients assigned to the placebo group took one 
sachet of placebo oral gel and one placebo capsule 
in the morning, one placebo capsule at noon and 
one placebo capsule in the evening. 
During the 3-month study, patients were allowed 
to take authorized NSAIDs if necessary and the 
daily consumption was recorded. The NSAIDs 
consumption was arbitrarily calculated as Diclofe- 
nac equivalent, considering that 150 mg of Diclofe- 
nac was equivalent o 900mg of Alminoprofen, 
400rag of Etodolac, 300rag of Flurbiprofen, 
2400mg of Ibuprofen, 100mg of Indometacin, 
300 mg of Ketoprofen, 1000 mg of Naproxen, 20 mg 
of Piroxicam, 1100mg of Sodium Naproxen and 
20 mg of Tenoxicam. 
Visit schedule and assessments 
The duration of the treatment foreseen by the 
protocol was 3 months (91 days) during which 
four clinical visits were fixed, at day 0 (DO, 
inclusion), D14, D42 and D91. The efficacy 
evaluation criteria were: 
9 Principal criterion: 
-a lgo - funct iona l  Lequesne's Index 
9 Secondary criteria: 
spontaneous pain on a visual analog scale 
(VAS) of 100 mm 
consumption of authorized NSAIDs during 
the treatment, calculated as Diclofenac equiv- 
alent (see 'Test drugs, dosage and adminis- 
tration') 
-overal l  judgement of both physician and 
patient. 
STATISTICAL ANALYSIS 
1. Comparison between groups: 
Comparison between the included groups 
was verified in using the Kruskall-Wallis 
nonparametric test, for the comparison of 
three groups regarding quantitative variables 
and the chi-square test of heterogeneity for 
qualitative variables. 
2. Efficacy and tolerance criteria: 
The investigation of efficacy and tolerance 
was carried on all of the included patients 
(intention-to-treat nalysis), in taking into 
account he last known value. The following 
two comparisons had been made: 
9 Chondrosulf 1200 mg/day versus placebo 
9 Chondrosulf 3 • 400 mg/day versus placebo 
A comparison of the evolution of the Lequesne's 
Index, of the visual analog scale and of the 
consumption of NSAIDs between day 0 and day 91, 
or between day 0 and the last known value, was 
Table I 
Patient's characteristics 
CS 1200 CS 3 • 400 
Chondroitin Chondroitin 
sulfate oral gel sulfate capsules PBO 
1200 mg/day 3 • 400 rag/day Placebo P value 
No. of patients at entry 40 43 44 
Men/women 16/26 8/34 7/37 0.09 
Age (mean _+ S.D.) 63 _+ 11 63 _+ 9 64 _+ 8 0.7 
Weight (mean _+ S.D.) 76 _+ 14 72 + 13 78 _+ 16 0.9 
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Table II 
Clinical status of the knee osteoarthritis n 127 patients at inclusion 
CS 1200 CS 3x400 Placebo 
Evaluation parameters (n = 40) (n = 43) (n = 44) P value 
Lequesne 
Mean values (S.D.) 11 (3) 10 (3) 10 (3) 0.7 
Median values (min max) 11(4.5 18.5) 10 (5 16) 10 (5-18) 
VAS (mm) 
Mean values (S.D.) 58 (13) 54 (12) 56 (13) 0.7 
Median values (min max) 61 (30 80) 55 (30-80) 56 (30-80) 
right 13 14 16 
left 9 13 10 0.9 
bilateral 18 16 18 
Symptomatic since (years) 
Mean values (S.D.) 
right 6 (5) 4 (4) 6 (5) 0.3 
left 5 (5) 5 (4) 6 (5) 0.7 
Median values (min raax) 
right 4 (0.7-25) 3 (1-15) 5 (1-20) 
left 3 (0.7-25) 5 (1 15) 4 (1-20) 
carr ied out with a nonparametr ic  test according to 
the progressive response of each patient.  
A comparison of the evolut ion of the to lerance 
score between day 0 and day 91, or between day 0 
and the last known value, was carr ied out with the 
Mantel  Haenzsel  chi-square test on the score 
value at day 0. 
The evolut ion dur ing the period of these 
judgement cr i ter ia was compared by the analyses 
of var iance for repeated measurements  on the rank 
variables. In addition, inside each of the three test 
groups, the stat ist ical  signif icance of the evolut ion 
dur ing the period of the judgement  cr i ter ia was 
tested by means of Wilcoxon's test for paired 
comparisons. 
Resu l ts  
A total  of 127 patients, 40 of whom were t reated 
with CS 1200, 43 with CS 3x400 and 44 with 
placebo, were included in this study (Table I). At 
baseline, the three groups were well balanced for 
sex, age, weight and height. 
The cl inical status of the knee osteoarthr i t is  was 
comparable  between the three groups of t reatment  
(Table II). 
LEQUESNE'S INDEX 
The score for Lequesne's  Index decreased in the 
three groups from DO to D91 (Table III). 
The reduct ion of the index was constant  in the 
two CS groups between DO and D91, about  
40-45% of its initial value, whereas in the 
PBO group it was approx imate ly  10% of its init ial 
value (Fig. 1). 
Statist ical ly, at D91 this reduct ion was signifi- 
cant ly greater  in the two CS groups than in the 
PBO group (P < 0.0001), it was already signif icant 
at D14 in the CS 1200 group (P<0.05)  and it 
became signif icant at D42 in the CS 3 x 400 group 
(P < 0.001). There was no signif icant difference 
between both CS groups for this criterion. 
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FIa. 1. Evolution of the Lequesne's Index score in % 
(mean+s.D.). -Q -=CS 1200; [] =CS 3x400; --A-- 
= PBO. 
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Table III 
Scores registered for the parameter 'algo-functional Lequesne's Index' at DO, D14, D42 and D91 in the different 
treatment groups 
CS 1200 CS 3 • 400 Placebo P value 
Algo-funetional Lequesne's Index (n = 40) (n = 43) (n = 44) (Wilcoxon-test) 
DO mean values (S.D.) 11 (3) 10 (3) 10 (3) 0.5 
median values (min-max) 11 (4.5-18.5) 10 (5 16) 10 (5-18) 
D14 mean values (S.D.) 9 (3) 9 (3) 10 (3) 0.4 
median values (min-max) 9 (1-14) 9 (5 16) 10 (2.5-17) 
D42 mean values (S.D.) 7 (3) 7 (2) 9 (3) 0.0005 
median values (min-max) 7 (0.5-14) 7 (2-13) 9 (2.5-18) 
D91 mean values (S.D.) 6 (3) 6 (3) 9 (4) 0.0001 
median values (min-max) 6 (1-12) 6 (1-13) 9 (2.5-19) 
Table IV 
VAS scores at DO, D14, D42 and D91 in the three treatment groups 
CS 1200 CS 3 • 400 Placebo P value 
VAS of the pain (mm) (n = 40) (n = 43) (n = 44) (Wilcoxon-test) 
DO mean values (S.D.) 58 (13) 54 (12) 56 (13) 0.4 
median values (rain max) 61 (30-80) 55 (30-80) 56 (30-80) 
D14 mean values (S.D.) 44 (19) 47 (16) 52 (16) 0.1 
median values (min max) 45 (5-76) 49 (6-90) 50 (20-83) 
D42 mean values (S.D.) 35 (17) 37 (18) 50 (18) 0.0009 
median values (min max) 37 (5-78) 41 (1-76) 50 (2-87) 
D91 mean values (S.D.) 29 (16) 28 (19) 45 (19) 0.0001 
median values (min-max) 26 (5-60) 26 ({~70) 48 (~80) 
VISUAL ANALOG SCALE (VAS) 
Table IV shows the levels of pain as measured by
the visual analog sca]e (VAS) in the three groups 
during the four visits. The decrease in VAS was 
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FIG. 2. VAS evolution in % (mean + S.D.).--O-- --CS 
1200; -M-  = CS 3 x 400; --A-- = PBO. 
constant between DO and D91 in the two groups 
treated with CS, whereas it was limited to the first 
14 days for the subjects treated with PBO (Fig. 2); 
measured in millimetres, the average reduction of 
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Table V 
Efficacy judgements expressed as a percentage by the physicians and patients 
Physicians Patients 
D42 D91 D42 D91 
Poor- Good- Poor- Good- Poor- Goo~ Poo~ Good- 
fair very good fair very good fair very good fair very good 
CS 1200 (n = 40) 32 
CS 3• (n = 43) 40 
PBO (n=44) 64 
68 31 69 32 68 29 71 
60 29 71 33 67 34 66 
36 66 34 62 38 66 34 
the VAS was almost the same for the two CS 
groups (29 and 26 mm respectively), and it was a 
l itt le more rapid in the CS 1200 group, whereas 
average reduct ion of VAS in the PBO group was 
only 10 mm. 
Statist ical ly, at D91, this drop was signif icantly 
greater  than in the PBO group (group CS 
1200P < 0.0001, group CS 3• P < 0.0005). 
Signif icance was reached for the CS 1200 as from 
D14 (P<0.01)  and from D42 for the CS 3x400 
group (P < 0.005). 
DAILY CONSUMPTION OF AUTHORIZED NSAID 
The reduct ion in consumption of author ized 
NSAIDs was aneva luat ion parameter  of the 
t reatment 's  efficacy. Measured in diclofenac equiv- 
alent, the reduct ion of the average daily consump- 
t ion between DO and D91 was 58 mg in the group 
treated with CS 1200, 56 mg in the group treated 
with CS 3x400, and 34 mg in the group adminis- 
tered PBO. All of these reduct ions are significant. 
The stat ist ical  compar ison between groups 
shows that  the reduct ion of the daily consumption 
of author ized NSAIDs was greater  in the subjects 
t reated with CS 1200 and CS 3x400 than in the 
subjects who received PBO (CS 1200 vs PBO 
P < 0.06, CS 3 x 400 vs PBO: P < 0.08). 
There was no signif icant difference in consump- 
tion of NSAIDs between the two CS groups at any 
of the times D14, D42 and D91. 
Figure 3 represents the percentage volut ion of 
NSAID consumption.  
OVERALL JUDGEMENT OF THE TREATMENT EFFICACY 
The efficacy of the t reatment  has been judged by 
the physic ian and the pat ient  on a four point 
verbal  scale: none, mediocre, good and very good. 
Concordance of judgements between physic ians 
and pat ients was very good; their  judgement  is 
described in Table V. 
There is a signif icant difference between chon- 
droit in sulfate t reatments  (CS 1200 and CS 3 • 400) 
and the placebo: at D42 P<0.05 ,  and at D91 
P < 0.01. 
On the other hand, there is no difference in 
efficacy between the t reatments  CS 1200 and CS 
3• either at D42 or at D91. 
OVERALL JUDGEMENT OF TREATMENT TOLERABILITY 
Tolerabi l i ty to the three treatments,  judged by 
both the physic ian and the patient, was very 
good. 
ADVERSE DRUG EVENTS (ADES) 
The occurrence of adverse drug events (ADEs) 
was reported in 28 cases (Table VI). Undesirable 
effects were, above all, digestive troubles: 21 cases, 
10 of which belonging to the placebo group 
reported gastralgia,  nausea, swollen stomach, 
vomiting, d iarrhea which, in most cases, c leared up 
spontaneously  or were resolved by classic symp- 
tomatic treatment.  They have led to t reatment  
suspension in six cases (one in CS 1200, two in CS 
3x400, three in PBO). A few cutaneous manifes- 
tations, four in total  of prur i tus or prurigi- nous 
eruption, were responsible in two cases of 
drop-out. Other ADEs, such as edema of the ankle, 
Table VI 
Adverse drug events that occurred during the trial 
period 
CS 1200 CS 3x400 Placebo 
Type of ADE (n = 40) (n -- 43) (n -- 44) 
Digestive 4 7 10 
Cutaneous 1 1 2 
Edema of the ankle 0 1 0 
Falling hair 1 0 0 
Extrasystoles 0 1 0 
Total 6 10 12 
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extra systoles and falling hair were reported by 
three patients. 
Discuss ion  
The results derived from several previous 
clinical trials, which evidenced the retarded [1-3] 
and lasting [44] action of the effects of chon- 
droitin sulfate 4&6 beyond the study end strongly 
suggested that taking the drug in a single daily 
dose of 1200 mg would have similar efficacy to that 
of three doses of 400mg. This assumption was 
confirmed by the trial. The good tolerability of CS 
oral gel has also been tested: adverse drug events 
were reported only in 28 cases. The number of 
ADEs was lower in the CS 1200 group (6 cases) 
than in the CS 3 x 400 group (10 cases) and in the 
PBO group (12 cases); most of ADEs seemed to be 
related to the associated treatment with NSAIDs, 
often responsible of this kind of effect. 
The three ADEs 'edema of the ankle', 'extrasys- 
toles' and 'falling hair' were considered as 
'unrelated' or 'remote' to the treatment. 
Conc lus ions  
The results of this comparative clinical study, in 
double-blind condition versus placebo, confirm the 
progressive fficacy of chondroitin CS 4&6 on the 
subjective painful symptomology and on the 
articular mobility in patients uffering from knee 
osteoarthritis. Furthermore, it demonstrates that 
chondroitin sulfate CS 4&6 has the same activity 
whether it be administered in the form of an oral 
gel with 1200 mg taken once daily or in the form of 
400 mg capsules taken three times per day. 
The concomitant consumption of NSAIDs was 
one of the parameters analysed: it decreased 
significantly in subjects treated with chondroitin 
sulfate as compared to those receiving a placebo 
and resulting in an economical advantage for the 
treatment of arthrosic patients. 
The tolerability of the two galenic forms of 
chondroitin sulfate studied and that of the placebo 
was very good. 
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